SNL  Vol.5 No.2 , April 2015
Aceclofenac-Soluplus&reg Nanocomposites for Increased Bioavailability
Aceclofenac is a new generational Non-Steroidal Anti-Inflammatory Drug (NSAID), and is considered a better alternative to the popular pain-killer diclofenac, as it overcomes some of the adverse gastrointestinal and cardiac side effects associated with the latter. However, the bioavailability of the drug remains limited due to low aqueous solubility (0.058 μg/mL) and poor dissolution characteristics. Hence, improving its dissolution characteristics is of prime significance in order to establish its optimal therapeutic efficacy. In an effort to tackle this issue, we report the use of novel Soluplus®-based nanocomposites, prepared from emulsion templates, as effective drug loading agent for aceclofenac. Nanoemulsion templates were prepared by high-shear homogenization using a probe sonicator. The emulsions were subsequently lyophilized to obtain free flowing powders. The amorphization of the drug with increasing polymer content was clearly observed from powder X-ray diffractogram, while the drug-polymer interaction was explored by FTIR spectroscopy. The phase purity and homogeneity of the formulation was characterized using Differential Scanning Calorimetry. The dissolution profiles of the formulations were established by an USP paddle apparatus. Phase solubility study was conducted to evaluate the effect of polymer concentration on aqueous solubility of aceclofenac. The values of Gibbs-free energy (ΔG°tr) associated with the aqueous solubility of aceclofenac in the presence of Soluplus was used to optimize the polymer content. The in vitro dissolution rates of aceclofenac from the nanoparticles were significantly higher compared to the pure drug. Thus, Soluplus nanoparticles provide promising formulations for the improvement of the dissolution profiles and thus, the bioavailability, of aceclofenac.

Cite this paper
Patnaik, S. , Aditha, S. , Rattan, T. and Kamisetti, V. (2015) Aceclofenac-Soluplus&reg Nanocomposites for Increased Bioavailability. Soft Nanoscience Letters, 5, 13-20. doi: 10.4236/snl.2015.52003.
[1]   Makhlof, A., Miyazaki, Y., Tozuka, Y. and Takeuchi, H. (2008) Cyclodextrins as Stabilizers for the Preparation of Drug Nanocrystals by the Emulsion Solvent Diffusion Method. International Journal of Pharmaceutics, 357, 280-285.

[2]   Gupta, U., Agashe, H.B., Asthana, A. and Jain, N.K. (2006) Dendrimers: Novel Polymeric Nanoarchitectures for Solubility Enhancement. Biomacromolecules, 7, 649-658.

[3]   Serajuddin, A.T.M. (2007) Salt Formation to Improve Drug Solubility. Advanced Drug Delivery Reviews, 59, 603-616.

[4]   Serajuddin, A.T.M. (1999) Solid Dispersion of Poorly Water-Soluble Drugs: Early Promises, Subsequent Problems, and Recent Breakthroughs. Journal of Pharmaceutical Sciences, 88, 1058-1066.

[5]   Chen, H., Khemtong, C., Yang, X., Chang, X. and Gao, J. (2011) Nanonization Strategies for Poorly Water-Soluble Drugs. Drug Discovery Today, 16, 354-360.

[6]   Yanagawa, A., Endo, T., Kusakari, K., Kudo, T., Shimada, J. and Mizushima, Y. (1998) Endoscopic Evaluation of Aceclofenac-Induced Gastroduodenal Mucosal Damage: A Double-Blind Comparison with Sodium Diclofenac and Placebo. The Journal of Rheumatology, 8, 249-259.

[7]   Maulvi, F.A., Dalwadi, S.J., Thakkar, V.T., Soni, T.G., Gohel, M.C. and Gandhi, T.R. (2010) Improvement of Dissolution Rate of Aceclofenac by Solid Dispersion Technique. Powder Technology, 207, 47-54.

[8]   Rupal, J., Kaushal, J., Mallikarjuna, S.C. and Dipti, P. (2009) Preparation and Evaluation of Solid Dispersions of Aceclofenac. Powder Technology, 1, 32-35.

[9]   Shakeel, F., Faisal, M.S. and Shafiq, S. (2009) Comparative Pharmacokinetic Profile of Aceclofenac from Oral and Transdermal Application. Journal of Bioequivalence & Bioavailability, 1, 013-017.

[10]   Ahmed, M.G., Gb, K.K., Bp, S.K. and Ar, H. (2010) Formulation and Evaluation of Solid Dispersion of Aceclofenac. International Journal of Advances in Pharmaceutical Sciences, 1, 77-82.

[11]   Katara, R. and Majumdar, D.K. (2013) Eudragit RL 100-Based Nanoparticulate System of Aceclofenac for Ocular Delivery. Colloids and Surfaces B: Biointerfaces, 103, 455-462.

[12]   Chawla, V. and Saraf, S.A. (2012) Rheological Studies on Solid Lipid Nanoparticle Based Carbopol Gels of Aceclofenac. Colloids and Surfaces B: Biointerfaces, 92, 293-298.

[13]   BASF (2010) Technical Information Soluplus. BASF, Pharma Ingredients & Services, 1-8.

[14]   Reintjes, T. (2011) Solubility Enhancement with BASF Pharma Polymers Solubilizer Compendium. BASF, Ludwigshafen.

[15]   Van den Mooter, G., Augustijns, P., Blaton, N. and Kinget, R. (1998) Physico-Chemical Characterization of Solid Dispersions of Temazepam with Polyethylene Glycol 6000 and PVP K30. International Journal of Pharmaceutics, 164, 67-80.

[16]   Rezaei Mokarram, A., Kebriaee Zadeh, A., Keshavarz, M., Ahmadi, A. and Mohtat, B. (2010) Preparation and in-Vitro Evaluation of Indomethacin Nanoparticles. Daru, 18, 185-192.

[17]   Barzegar-Jalali, M., Alaei-Beiramib, M., Javadzadeha, Y., Mohammadic, G., Hamidia, A., Andalibb, S. and Adibkia, K. (2012) Comparison of Physicochemical Characteristics and Drug Release of Diclofenac Sodium-Eudragit° RS100 Nanoparticles and Solid Dispersions. Powder Technology, 219, 211-216.

[18]   Merisko-Liversidge, E.M. and Liversidge, G.G. (2008) Drug Nanoparticles: Formulating Poorly Water-Soluble Compounds. Toxicologic Pathology, 36, 43-48.

[19]   Kim, M.-S. (2013) Soluplus-Coated Colloidal Silica Nanomatrix System for Enhanced Supersaturation and Oral Absorption of Poorly Water-Soluble Drugs. Artificial Cells, Nanomedicine and Biotechnology, 41, 363-367.